NEW YORK (GenomeWeb News) – Ciphergen Biosystems today said its shares have regained compliance with the Nasdaq exchange after it allowed the company to move its shares to its Capital Market from the National Market.
To remain listed on the Capital Market Ciphergen must, among other things, have a market capitalization greater than $35 million, the company said in a Securities and Exchange Commission filing today. Ciphergen’s market cap is currently around $48 million.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.